MENU
PBPH
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

PBPH stock forecast, quote, news & analysis

The investment seeks to track the performance, before fees and expenses, of the BITA Global Pharma and Biotech Select Index... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
PBPH
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for PBPH with price predictions
Oct 21, 2026

PBPH in upward trend: price rose above 50-day moving average on October 14, 2026

PBPH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 5 of 5 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PBPH as a result. In 17 of 19 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for PBPH just turned positive on October 14, 2026. Looking at past instances where PBPH's MACD turned positive, the stock continued to rise in 6 of 7 cases over the following month. The odds of a continued upward trend are 86%.

The 10-day moving average for PBPH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 1 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +4.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBPH advanced for three days, in 36 of 45 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

PBPH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PBPH entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN).

Industry description

The investment seeks to track the performance, before fees and expenses, of the BITA Global Pharma and Biotech Select Index. The fund uses a “passive management” approach to track the performance, before fees and expenses, of the index. The index is constructed using a rules-based methodology that identifies companies in the pharmaceutical and/or biotechnology industries with publicly traded ordinary shares listed on major stock exchanges in developed markets, as classified by BITA GmbH. Under normal circumstances, the fund will invest at least 80% of the fund’s net assets in component securities that make up the index. The fund is non-diversified.

Market Cap

The average market capitalization across the Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) ETF is 226.06B. The market cap for tickers in the group ranges from 10.69B to 1.13T. LLY holds the highest valuation in this group at 1.13T. The lowest valued company is BMRN at 10.69B.

High and low price notable news

The average weekly price growth across all stocks in the Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) ETF was 14%. For the same ETF, the average monthly price growth was 21%, and the average quarterly price growth was 299%. ROIV experienced the highest price growth at 9%, while INSM experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) ETF was -28%. For the same stocks of the ETF, the average monthly volume growth was -6% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 65
P/E Growth Rating: 48
Price Growth Rating: 29
SMR Rating: 56
Profit Risk Rating: 43
Seasonality Score: 26 (-100 ... +100)
PBPH in upward trend: price rose above 50-day moving average on October 14, 2026